Abstract
| Language | English |
|---|---|
| Pages | 608-612 |
| Number of pages | 4 |
| Journal | Current Opinion in Biotechnology |
| Volume | 19 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2008 |
Fingerprint
Keywords
- bacteriophage therapy
- animal
- human trials
Cite this
}
Bacteriophage therapy - cooked goose or Phoenix rising? / Mattey, M.; Spencer, J.
In: Current Opinion in Biotechnology, Vol. 19, No. 6, 12.2008, p. 608-612.Research output: Contribution to journal › Article
TY - JOUR
T1 - Bacteriophage therapy - cooked goose or Phoenix rising?
AU - Mattey, M.
AU - Spencer, J.
PY - 2008/12
Y1 - 2008/12
N2 - Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.
AB - Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.
KW - bacteriophage therapy
KW - animal
KW - human trials
U2 - 10.1016/j.copbio.2008.09.001
DO - 10.1016/j.copbio.2008.09.001
M3 - Article
VL - 19
SP - 608
EP - 612
JO - Current Opinion in Biotechnology
T2 - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
SN - 0958-1669
IS - 6
ER -